Sector
PharmaceuticalsOpen
₹2.41Prev. Close
₹2.4Turnover(Lac.)
₹0.3Day's High
₹2.52Day's Low
₹2.452 Week's High
₹4.5652 Week's Low
₹2.32Book Value
₹-55.78Face Value
₹10Mkt Cap (₹ Cr.)
6P/E
0EPS
0Divi. Yield
0
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 23.83 | 23.83 | 23.83 | 23.83 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -151.81 | -146.25 | -131.03 | -111.8 |
Net Worth | -127.98 | -122.42 | -107.2 | -87.97 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | -100 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -1.39 | -1.79 | -2.42 | -3.11 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -19.23 | -21 | -23.92 | -19.23 |
Depreciation | -5.63 | -5.87 | -6.44 | -6.78 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -3.83 | -4.65 | -3.11 | 7.09 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | -100 |
Op profit growth | 305.58 | -77.23 | -25.31 | -184.17 |
EBIT growth | 28.46 | -30.7 | 95.07 | 131.74 |
Net profit growth | -8.44 | -12.19 | 24.35 | 16.88 |
| Particulars (Rupees in Crores.) | Mar-2014 | Mar-2013 | Mar-2012 | Mar-2011 |
|---|---|---|---|---|
Gross Sales | 103.19 | 403.66 | 287.26 | 162.12 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 103.19 | 403.66 | 287.26 | 162.12 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 0.25 | 0.37 | 0.23 | 0.25 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,679.8 | 94.26 | 4,03,040.29 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,883 | 82.72 | 1,82,722.02 | 667 | 0.44 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,510.85 | 25.35 | 1,22,032.54 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,350.6 | 59.93 | 1,13,394.44 | 474 | 0.18 | 2,385 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,310.05 | 20.32 | 1,09,334.39 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Ajit Kamath
Non-Exec & Non-Independent Dir
Rajendra Kaimal
Company Sec. & Compli. Officer
Jignesh Patel
Non-Exec. & Independent Dir.
Sunil Pitroda
Non-Exec. & Independent Dir.
Abhishek Buddhadev
Non-Exec. & Independent Dir.
Urja Shah
Ground Flr D No 8-2-684/J/8/A,
Bhavani Nagar Banjara Hills,
Telangana - 500034
Tel: -
Website: http://www.kobobiotech.com
Email: info@kobobiotech.com
Plot No 3 Sagar Soci,
Road No 2, Banjara Hills,
Hyderabad - 500034
Tel: 91-40-23545913/4/5
Website: www.xlsoftech.com
Email: xlfield@rediffmail.com
Summary
Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3, 1992. Effective 19th October, 2020, the Companys name was changed to Kobo Biotech Limit...
Read More
Reports by Kobo Biotech Ltd
What is the Kobo Biotech Ltd share price today?
What is the Market Cap of Kobo Biotech Ltd?
What is the PE and PB ratio of Kobo Biotech Ltd?
What is the 52 Week High and Low of Kobo Biotech Ltd?
What is the CAGR of Kobo Biotech Ltd?
What is the shareholding pattern of Kobo Biotech Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
